Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 6/20 | 0.33 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.32 |
| ▸ | PDE2A | O00408 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 2/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.30 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16327866 | 0.88 | ALOX5AP (0.38) | ALOX5APACSS2PPARGAGTR1AGTR2 | |
| SCHEMBL16327762 | 0.88 | AGTR2 (0.35) | ALOX5APACSS2PPARGS1PR4PDE2A | |
| SCHEMBL12884191 | 0.88 | CSF1R (0.40) | ALOX5APACSS2 | |
| SCHEMBL16327763 | 0.88 | F2 (0.35) | ALOX5APACSS2PPARGPDE2AAGTR1 | |
| SCHEMBL8252433 | 0.85 | S1PR4 (0.36) | S1PR4PDE2APDE10AMAPTAGTR1 | |
| SCHEMBL12884199 | 0.77 | CSF1R (0.38) | ALOX5APACSS2PPARGMAPT | |
| SCHEMBL12884205 | 0.76 | CSF1R (0.41) | ALOX5APACSS2MAPT | |
| SCHEMBL12884204 | 0.76 | CSF1R (0.39) | ALOX5APACSS2 | |
| SCHEMBL8247680 | 0.75 | TLR8 (0.42) | — | |
| SCHEMBL8251906 | 0.75 | AGTR2 (0.39) | ALOX5APACSS2S1PR4AGTR1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7884215-B2 | 2-substituted benzimidazoles | JANSSEN SCIENCES IRELAND UC (IE) | 2011-02-08 | — | — | US | disclosed |
| US-20100092426-A1 | 2-SUBSTITUTED BENZIMIDAZOLES | JANSSEN SCIENCES IRELAND UC (IE) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100092426-A1 | 2-SUBSTITUTED BENZIMIDAZOLES | HTR4, HRH4, HTR3C | ALOX5AP 4135/4885ACSS2 2168/4885PPARG 3473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.